Education
About Us
Working with TipRanks
Follow Us
Jasper Therapeutics (JSPR)
NASDAQ:JSPR
JSPR Stock Chart & Stats
$1.64
-$10.02(-56.58%)
At close: 4:00 PM EST
$1.64
-$10.02(-56.58%)
Day’s Range― - ―
52-Week Range$1.39 - $7.19
Previous CloseN/A
Volume4.28M
Average Volume (3M)399.98K
Market Cap
$45.89M
Enterprise Value-$23.35M
Total Cash (Recent Filing)$50.90M
Total Debt (Recent Filing)$1.70M
Price to Earnings (P/E)―
Beta2.61
Next Earnings
Mar 10, 2026EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding27,984,040
10 Day Avg. Volume455,991
30 Day Avg. Volume399,984
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)5.06
Price to Sales (P/S)0.00
P/FCF Ratio-4.94
Enterprise Value/Market Cap-0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.25
Forecast
1Y Price Target
$12.00Price Target Upside631.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DurabilityUpdated trial results report rapid onset of symptom relief with high rates of complete response and sustained disease control in extension studies, supporting the therapy's efficacy and durability.
Program De-risking And Development ClarityIndependent review and investigations attributed anomalous nonresponse to misdiagnosis and site conduct rather than drug product, enabling clearer dose selection for the planned adaptive Phase 2b/3 program and drawing potential partner interest.
Safety And TolerabilitySafety data indicate the therapy is generally well tolerated, with KIT-related adverse events described as infrequent, low-grade, and transient, improving the clinical risk profile.
Bears Say
Dosing Uncertainty And VariabilityVariability in patient response linked to weight and temporary efficacy dips near dosing intervals creates uncertainty around the optimal dose and schedule needed to sustain benefit while limiting on-target side effects.
Financing RiskNeed to secure additional financing to support the planned Phase 2b study increases dilution and execution risk if access to capital becomes constrained.
Patient Selection And Site ConductEvidence of misdiagnosed patients and improper injection methods at a clinical site undermines trial data reliability and may complicate future enrollment and interpretation of results.
Jasper Therapeutics News
JSPR FAQ
What was Jasper Therapeutics’s price range in the past 12 months?
Jasper Therapeutics lowest stock price was $1.39 and its highest was $7.19 in the past 12 months.
What is Jasper Therapeutics’s market cap?
Jasper Therapeutics’s market cap is $45.89M.
When is Jasper Therapeutics’s upcoming earnings report date?
Jasper Therapeutics’s upcoming earnings report date is Mar 10, 2026 which is in 40 days.
How were Jasper Therapeutics’s earnings last quarter?
Jasper Therapeutics released its earnings results on Nov 10, 2025. The company reported -$1.13 earnings per share for the quarter, beating the consensus estimate of -$1.215 by $0.085.
Is Jasper Therapeutics overvalued?
According to Wall Street analysts Jasper Therapeutics’s price is currently Undervalued.
Does Jasper Therapeutics pay dividends?
Jasper Therapeutics does not currently pay dividends.
What is Jasper Therapeutics’s EPS estimate?
Jasper Therapeutics’s EPS estimate is -0.67.
How many shares outstanding does Jasper Therapeutics have?
Jasper Therapeutics has 27,984,040 shares outstanding.
What happened to Jasper Therapeutics’s price movement after its last earnings report?
Jasper Therapeutics reported an EPS of -$1.13 in its last earnings report, beating expectations of -$1.215. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Jasper Therapeutics?
Currently, no hedge funds are holding shares in JSPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jasper Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (631.71% Upside)
$12.00 (631.71% Upside)
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.39%
12-Months-Change
Fundamentals
Return on Equity
-191.12%
Trailing 12-Months
Asset Growth
-42.19%
Trailing 12-Months
Company Description
Jasper Therapeutics
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
JSPR Stock 12 Month Forecast
Average Price Target
$12.00
▲(631.71% Upside)
Technical Analysis
Ownership Overview
1.34% Insiders
6.16% Mutual Funds
55.07% Other Institutional Investors
33.76% Public Companies and Individual Investors